Inhibiting poly ADP-ribosylation increases fatty acid oxidation and protects against fatty liver disease

Journal of Hepatology

Volumn 66, Issue 1, 2017, Pages 132-141

  Gariani, Karim ^a   Ryu, Dongryeol ^a   Menzies, Keir J ^a,b   Yi, Hyon Seung ^d   Stein, Sokrates ^a,c   Zhang, Hongbo ^a   Perino, Alessia ^a   Lemos, Vera ^a   Katsyuba, Elena ^a   Jha, Pooja ^a   Vijgen, Sandrine ^e   Rubbia Brandt, Laura ^e   Kim, Yong Kyung ^d   Kim, Jung Tae ^d   Kim, Koon Soon ^d   Shong, Minho ^d   Schoonjans, Kristina ^a   Auwerx, Johan ^a  

^a EPFL   (Switzerland)

^b UNIVERSITY OF OTTAWA   (Canada)

^c UNIVERSITY OF ZURICH   (Switzerland)

^d Chungnam National University   (South Korea)

^e GENEVA UNIVERSITY HOSPITALS   (Switzerland)

Author keywords

NAD; Non alcoholic fatty liver disease; PARP inhibitor; PARylation; Poly ADP ribosylation; Sirtuin

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; CHOLESTEROL; FATTY ACID; GLUCOSE; NICOTINAMIDE ADENINE DINUCLEOTIDE; OLAPARIB; REACTIVE OXYGEN METABOLITE; SIRTUIN; TRANSCRIPTOME; TRIACYLGLYCEROL; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; PHTHALAZINE DERIVATIVE; PIPERAZINE DERIVATIVE;

ADENOSINE DIPHOSPHATE RIBOSYLATION; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CONTROLLED STUDY; DRUG EFFICACY; ENDOPLASMIC RETICULUM STRESS; ENZYME ACTIVATION; ENZYME INHIBITION; FATTY ACID OXIDATION; GLUCOSE HOMEOSTASIS; HUMAN; LIPID DIET; LIPID LIVER LEVEL; LIVER FIBROSIS; LIVER PROTECTION; MALE; MITOCHONDRIAL BIOGENESIS; MITOCHONDRIAL DYNAMICS; MOLECULARLY TARGETED THERAPY; MOUSE; NONALCOHOLIC FATTY LIVER; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; SUGAR INTAKE; ANIMAL; DISEASE MODEL; LIPID METABOLISM; LIVER; METABOLISM; OXIDATION REDUCTION REACTION; PATHOLOGY;

ANIMALS; DISEASE MODELS, ANIMAL; LIPID METABOLISM; LIVER; MICE; NON-ALCOHOLIC FATTY LIVER DISEASE; OXIDATION-REDUCTION; PHTHALAZINES; PIPERAZINES; POLY(ADP-RIBOSE) POLYMERASE INHIBITORS; POLY(ADP-RIBOSE) POLYMERASES;

EID: 85008145303     PISSN: 01688278     EISSN: 16000641     Source Type: Journal    
DOI: 10.1016/j.jhep.2016.08.024     Document Type: Article

References (53)

1. [1] Chalasani, N., Younossi, Z., Lavine, J.E., Diehl, A.M., Brunt, E.M., Cusi, K., et al. The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology 55 (2012), 2005–2023.
2. [2] Ng, M., Fleming, T., Robinson, M., Thomson, B., Graetz, N., Margono, C., et al. Global, regional, and national prevalence of overweight and obesity in children and adults during 1980–2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet 384 (2014), 766–781.
3. [3] Gariani, K., Philippe, J., Jornayvaz, F.R., Non-alcoholic fatty liver disease and insulin resistance: from bench to bedside. Diabetes Metab 39 (2013), 16–26.
4. [4] Sattar, N., Forrest, E., Preiss, D., Non-alcoholic fatty liver disease. BMJ, 349, 2014, g4596.
5. [5] Charlton, M.R., Burns, J.M., Pedersen, R.A., Watt, K.D., Heimbach, J.K., Dierkhising, R.A., Frequency and outcomes of liver transplantation for nonalcoholic steatohepatitis in the United States. Gastroenterology 141 (2011), 1249–1253.
6. [6] Wong, R.J., Aguilar, M., Cheung, R., Perumpail, R.B., Harrison, S.A., Younossi, Z.M., et al. Nonalcoholic steatohepatitis is the second leading etiology of liver disease among adults awaiting liver transplantation in the United States. Gastroenterology 148 (2015), 547–555.
7. [7] Orci, L.A., Gariani, K., Oldani, G., Delaune, V., Morel, P., Toso, C., Exercise-based interventions for nonalcoholic fatty liver disease: a meta-analysis and meta-regression. Clin Gastroenterol Hepatol 14 (2016), 1398–1411.
8. [8] Keating, S.E., Hackett, D.A., George, J., Johnson, N.A., Exercise and non-alcoholic fatty liver disease: a systematic review and meta-analysis. J Hepatol 57 (2012), 157–166.
9. [9] Musso, G., Cassader, M., Gambino, R., Non-alcoholic steatohepatitis: emerging molecular targets and therapeutic strategies. Nat Rev Drug Discovery 15 (2016), 249–274.
10. [10] Koliaki, C., Szendroedi, J., Kaul, K., Jelenik, T., Nowotny, P., Jankowiak, F., et al. Adaptation of hepatic mitochondrial function in humans with non-alcoholic fatty liver is lost in steatohepatitis. Cell Metab 21 (2015), 739–746.
11. [11] Gariani, K., Menzies, K.J., Ryu, D., Wegner, C.J., Wang, X., Ropelle, E.R., et al. Eliciting the mitochondrial unfolded protein response via NAD repletion reverses fatty liver disease. Hepatology 63 (2016), 1190–1204.
12. [12] Perez-Carreras, M., Del Hoyo, P., Martin, M.A., Rubio, J.C., Martin, A., Castellano, G., et al. Defective hepatic mitochondrial respiratory chain in patients with nonalcoholic steatohepatitis. Hepatology 38 (2003), 999–1007.
13. [13] Serviddio, G., Bellanti, F., Tamborra, R., Rollo, T., Romano, A.D., Giudetti, A.M., et al. Alterations of hepatic ATP homeostasis and respiratory chain during development of non-alcoholic steatohepatitis in a rodent model. Eur J Clin Invest 38 (2008), 245–252.
14. [14] Wree, A., Broderick, L., Canbay, A., Hoffman, H.M., Feldstein, A.E., From NAFLD to NASH to cirrhosis-new insights into disease mechanisms. Nat Rev Gastroenterol Hepatol 10 (2013), 627–636.
15. [15] Cortez-Pinto, H., Chatham, J., Chacko, V.P., Arnold, C., Rashid, A., Diehl, A.M., Alterations in liver ATP homeostasis in human nonalcoholic steatohepatitis: a pilot study. JAMA 282 (1999), 1659–1664.
16. [16] Petrosillo, G., Portincasa, P., Grattagliano, I., Casanova, G., Matera, M., Ruggiero, F.M., et al. Mitochondrial dysfunction in rat with nonalcoholic fatty liver Involvement of complex I, reactive oxygen species and cardiolipin. Biochim Biophys Acta 1767 (2007), 1260–1267.
17. [17] Cerutti, R., Pirinen, E., Lamperti, C., Marchet, S., Sauve, A.A., Li, W., et al. NAD(+)-dependent activation of Sirt1 corrects the phenotype in a mouse model of mitochondrial disease. Cell Metab 19 (2014), 1042–1049.
18. [18] Pirinen, E., Canto, C., Jo, Y.S., Morato, L., Zhang, H., Menzies, K.J., et al. Pharmacological Inhibition of poly(ADP-ribose) polymerases improves fitness and mitochondrial function in skeletal muscle. Cell Metab 19 (2014), 1034–1041.
19. [19] Bai, P., Canto, C., Oudart, H., Brunyanszki, A., Cen, Y., Thomas, C., et al. PARP-1 inhibition increases mitochondrial metabolism through SIRT1 activation. Cell Metab 13 (2011), 461–468.
20. [20] Scheibye-Knudsen, M., Mitchell, S.J., Fang, E.F., Iyama, T., Ward, T., Wang, J., et al. A high-fat diet and NAD(+) activate Sirt1 to rescue premature aging in cockayne syndrome. Cell Metab 20 (2014), 840–855.
21. [21] Bai, P., Canto, C., The role of PARP-1 and PARP-2 enzymes in metabolic regulation and disease. Cell Metab 16 (2012), 290–295.
22. [22] Canto, C., Auwerx, J., Targeting sirtuin 1 to improve metabolism: all you need is NAD(+)?. Pharmacol Rev 64 (2012), 166–187.
23. [23] Houtkooper, R.H., Canto, C., Wanders, R.J., Auwerx, J., The secret life of NAD+: an old metabolite controlling new metabolic signaling pathways. Endocr Rev 31 (2010), 194–223.
24. [24] Canto, C., Menzies, K.J., Auwerx, J., NAD(+) metabolism and the control of energy homeostasis: a balancing act between mitochondria and the nucleus. Cell Metab 22 (2015), 31–53.
25. [25] Menzies, K.J., Zhang, H., Katsyuba, E., Auwerx, J., Protein acetylation in metabolism – metabolites and cofactors. Nat Rev Endocrinol 12 (2016), 43–60.
26. [26] Pillai, J.B., Isbatan, A., Imai, S., Gupta, M.P., Poly(ADP-ribose) polymerase-1-dependent cardiac myocyte cell death during heart failure is mediated by NAD+ depletion and reduced Sir2alpha deacetylase activity. J Biol Chem 280 (2005), 43121–43130.
27. [27] Mouchiroud, L., Houtkooper, R.H., Moullan, N., Katsyuba, E., Ryu, D., Canto, C., et al. The NAD(+)/sirtuin pathway modulates longevity through activation of mitochondrial UPR and FOXO signaling. Cell 154 (2013), 430–441.
28. [28] Jo, Y.S., Ryu, D., Maida, A., Wang, X., Evans, R.M., Schoonjans, K., et al. Phosphorylation of the nuclear receptor corepressor 1 by protein kinase B switches its corepressor targets in the liver in mice. Hepatology 62 (2015), 1606–1618.
29. [29] Ryu, D., Jo, Y.S., Lo Sasso, G., Stein, S., Zhang, H., Perino, A., et al. A SIRT7-dependent acetylation switch of GABPbeta1 controls mitochondrial function. Cell Metab 20 (2014), 856–869.
30. [30] Jha, P., Wang, X., Auwerx, J., Analysis of mitochondrial respiratory chain supercomplexes using blue native polyacrylamide gel electrophoresis (BN-PAGE). Curr Protoc Mouse Biol 6 (2016), 1–14.
31. [31] Yang, T., Sauve, A.A., NAD metabolism and sirtuins: metabolic regulation of protein deacetylation in stress and toxicity. AAPS J 8 (2006), E632–E643.
32. [32] Stein, S., Oosterveer, M.H., Mataki, C., Xu, P., Lemos, V., Havinga, R., et al. SUMOylation-dependent LRH-1/PROX1 interaction promotes atherosclerosis by decreasing hepatic reverse cholesterol transport. Cell Metab 20 (2014), 603–613.
33. [33] Ahrens, M., Ammerpohl, O., von Schonfels, W., Kolarova, J., Bens, S., Itzel, T., et al. DNA methylation analysis in nonalcoholic fatty liver disease suggests distinct disease-specific and remodeling signatures after bariatric surgery. Cell Metab 18 (2013), 296–302.
34. [34] Affo, S., Dominguez, M., Lozano, J.J., Sancho-Bru, P., Rodrigo-Torres, D., Morales-Ibanez, O., et al. Transcriptome analysis identifies TNF superfamily receptors as potential therapeutic targets in alcoholic hepatitis. Gut 62 (2013), 452–460.
35. [35] Neumann, O., Kesselmeier, M., Geffers, R., Pellegrino, R., Radlwimmer, B., Hoffmann, K., et al. Methylome analysis and integrative profiling of human HCCs identify novel protumorigenic factors. Hepatology 56 (2012), 1817–1827.
36. [36] Duval, C., Thissen, U., Keshtkar, S., Accart, B., Stienstra, R., Boekschoten, M.V., et al. Adipose tissue dysfunction signals progression of hepatic steatosis towards nonalcoholic steatohepatitis in C57BL/6 mice. Diabetes 59 (2010), 3181–3191.
37. [37] Verbeek, J., Lannoo, M., Pirinen, E., Ryu, D., Spincemaille, P., Vander Elst, I., et al. Roux-en-y gastric bypass attenuates hepatic mitochondrial dysfunction in mice with non-alcoholic steatohepatitis. Gut 64 (2015), 673–683.
38. [38] Zhang, K., Kaufman, R.J., From endoplasmic-reticulum stress to the inflammatory response. Nature 454 (2008), 455–462.
39. [39] Puri, P., Mirshahi, F., Cheung, O., Natarajan, R., Maher, J.W., Kellum, J.M., et al. Activation and dysregulation of the unfolded protein response in nonalcoholic fatty liver disease. Gastroenterology 134 (2008), 568–576.
40. [40] Ryu, D., Seo, W.Y., Yoon, Y.S., Kim, Y.N., Kim, S.S., Kim, H.J., et al. Endoplasmic reticulum stress promotes LIPIN2-dependent hepatic insulin resistance. Diabetes 60 (2011), 1072–1081.
41. [41] Zinszner, H., Kuroda, M., Wang, X., Batchvarova, N., Lightfoot, R.T., Remotti, H., et al. CHOP is implicated in programmed cell death in response to impaired function of the endoplasmic reticulum. Genes Dev 12 (1998), 982–995.
42. [42] Hotamisligil, G.S., Endoplasmic reticulum stress and the inflammatory basis of metabolic disease. Cell 140 (2010), 900–917.
43. [43] Malhi, H., Kaufman, R.J., Endoplasmic reticulum stress in liver disease. J Hepatol 54 (2011), 795–809.
44. [44] Farrell, G.C., van Rooyen, D., Gan, L., Chitturi, S., NASH is an inflammatory disorder: pathogenic, prognostic and therapeutic implications. Gut Liver 6 (2012), 149–171.
45. [45] Halliwell, B., Reactive oxygen species in living systems: source, biochemistry, and role in human disease. Am J Med 91 (1991), 14S–22S.
46. [46] Fisher, F.M., Chui, P.C., Nasser, I.A., Popov, Y., Cunniff, J.C., Lundasen, T., et al. Fibroblast growth factor 21 limits lipotoxicity by promoting hepatic fatty acid activation in mice on methionine and choline-deficient diets. Gastroenterology, 147, 2014, e1076.
47. [47] Mukhopadhyay, P., Rajesh, M., Cao, Z., Horvath, B., Park, O., Wang, H., et al. Poly (ADP-ribose) polymerase-1 is a key mediator of liver inflammation and fibrosis. Hepatology 59 (2014), 1998–2009.
48. [48] Canto, C., Houtkooper, R.H., Pirinen, E., Youn, D.Y., Oosterveer, M.H., Cen, Y., et al. The NAD(+) precursor nicotinamide riboside enhances oxidative metabolism and protects against high-fat diet-induced obesity. Cell Metab 15 (2012), 838–847.
49. [49] Luo, X., Kraus, W.L., On PAR with PARP: cellular stress signaling through poly(ADP-ribose) and PARP-1. Genes Dev 26 (2012), 417–432.
50. [50] Rolo, A.P., Teodoro, J.S., Palmeira, C.M., Role of oxidative stress in the pathogenesis of nonalcoholic steatohepatitis. Free Radical Biol Med 52 (2012), 59–69.
51. [51] Gregor, M.F., Yang, L., Fabbrini, E., Mohammed, B.S., Eagon, J.C., Hotamisligil, G.S., et al. Endoplasmic reticulum stress is reduced in tissues of obese subjects after weight loss. Diabetes 58 (2009), 693–700.
52. [52] Varela-Rey, M., Embade, N., Ariz, U., Lu, S.C., Mato, J.M., Martinez-Chantar, M.L., Non-alcoholic steatohepatitis and animal models: understanding the human disease. Int J Biochem Cell Biol 41 (2009), 969–976.
53. [53] Marmier, S., Dentin, R., Daujat-Chavanieu, M., Guillou, H., Bertrand-Michel, J., Gerbal-Chaloin, S., et al. Novel role for carbohydrate responsive element binding protein in the control of ethanol metabolism and susceptibility to binge drinking. Hepatology 62 (2015), 1086–1100.